<DOC>
	<DOCNO>NCT00622258</DOCNO>
	<brief_summary>This study assess tolerability , safety , efficacy pharmacokinetics everolimus Japanese patient . Everolimus administer orally everyday adult patient relapse refractory non-Hodgkin 's lymphoma progress despite standard therapy standard systemic therapy dose exist .</brief_summary>
	<brief_title>A Phase I Dose Escalation Study RAD001 Administered Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : Patients must histopathologically confirm diagnosis nonHodgkin 's lymphoma Patients must disease either relapsed refractory least one prior treatment regimen must eligible standard treatment Patients must receive autologous stem cell transplant least within 12 week prior study treatment . If patient receive autologous stem cell transplant 12 week ago , must fully recover side effect treatment Patients receive autologous stem cell transplant must either ineligible treatment , eligible , patient must choose receive stem cell transplant Patients must least one measurable lesion Age 20 year old Performance Status 0 , 1 , 2 Eastern Cooperative Oncology Group ( ECOG ) scale Patients life expectancy least 12 week Patients must willing provide portion bone marrow aspirate biopsy study Exclusion criterion : Patients history another primary malignancy currently clinically significant currently require active intervention Patients prior allogeneic stem cell transplant Patients recover side effect major surgery ( define require general anesthesia ) patient may require major surgery course study Patients receive radiation therapy ≤ 28 day prior first study treatment recover side effect therapy . Patients receive investigational agent ≤28 day prior first study treatment Patients receive antineoplastic therapy within 28 day ( 60 day monoclonal antibody radioimmunotherapy ) prior first study treatment recover side effect therapy Patients receive treatment oral intravenous steroid immunosuppressive agent ≤ 28 day prior first study treatment Patients receive prior therapy RAD001 mTOR inhibitor Patient prior therapy &gt; 450 U blomycin Patients active , bleeding diathesis . Treatment hematopoietic colonystimulating growth factor ( e.g. , GCSF ) ≤ 14 day prior first study treatment Patients impairment gastrointestinal function gastrointestinal disease may significantly alter absorption study treatment ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome ) Patients active respiratory ( exclude interstitial lung disease ) , skin , mucosal , renal , neurological , ocular disorder grade &gt; 1 Patients history interstitial lung disease grade ≥ 1 Patients known history human immunodeficiency virus seropositivity , hepatitis B C seropositivity Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>everolimus</keyword>
	<keyword>mTOR inhibitor</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
</DOC>